http://www.huffingtonpost.com/christiane-northrup/buyer-beware-statins-are_b_246566.htmlHalf the people who have heart attacks have normal cholesterol (even though guidelines have been repeatedly changed since the 80s to put an ever-increasing % of the population on statins).
DOING THE MATH
The second crucial point is hiding in plain sight in Pfizer's own Lipitor newspaper ad. The dramatic 36% figure has an asterisk. Read the smaller type. It says: "That means in a large clinical study, 3% of patients taking a sugar pill or placebo had a heart attack compared to 2% of patients taking Lipitor."
Now do some simple math. The numbers in that sentence mean that for every 100 people in the trial, which lasted 3 1/3 years, three people on placebos and two people on Lipitor had heart attacks. The difference credited to the drug? One fewer heart attack per 100 people. So to spare one person a heart attack, 100 people had to take Lipitor for more than three years. The other 99 got no measurable benefit. Or to put it in terms of a little-known but useful statistic, the number needed to treat (or NNT) for one person to benefit is 100.
Compare that with, say, today's standard antibiotic therapy to eradicate ulcer-causing H. pylori stomach bacteria. The NNT is 1.1. Give the drugs to 11 people, and 10 will be cured...
Plus, there are reasons to believe the overall benefit for many patients is even less than what the NNT score of 100 suggests. That NNT was determined in an industry-sponsored trial using carefully selected patients with multiple risk factors, which include high blood pressure or smoking. In contrast, the only large clinical trial funded by the government, rather than companies, found no statistically significant benefit at all. And because clinical trials themselves suffer from potential biases, results claiming small benefits are always uncertain, says Dr. Nortin M. Hadler, professor of medicine at the University of North Carolina at Chapel Hill and a longtime drug industry critic. "Anything over an NNT of 50 is worse than a lottery ticket;
http://www.businessweek.com/magazine/content/08_04/b4068052092994_page_2.htmWhen the cholesterol guidelines were revised 2001 I (non-scientific routine dietitian chart reviews in a small rural hospital) started noticing more diagnoses of rhabdomyolois. I'd not been familiar with it until then; in my med refs it was described as "rare". It's my *opinion* the increase in cases was related to increased statin use at increased rx levels. It's also my opinion that numbers of cases aren't investigated as r/t statins. Even when pt. was on statins, some docs wouldn't make the connection, & I didn't initially make it either until i read up after wondering why i kept seeing patients with this "rare" dx.
e.g.:
"Rhabdomyolysis is a relatively rare condition in everyday life. The rate of rhabdomyolysis in the general population is difficult to establish with certainty, but was estimated by one U.S. study to be about 2 cases per 10,000 person-years.<20> Another study found 26,000 cases per year in the U.S."
http://en.wikipedia.org/wiki/Rhabdomyolysis& of course, there's the general level of politics & graft involved in "expert panels" for drug approvals these days.
http://www.latimes.com/news/printedition/la-na-nih22dec22,0,1505130.story